Table 2.
Biological activity of massatide A against clinic isolated resistant strains (μg/mL)
| Strains | Massatide A(1) | Levofloxacin | |
|---|---|---|---|
| G+ | MRSA 15-1 | 2 | 16 |
| LRSA 20-1 | 0.25 | 32 | |
| MRSA ATCC33591 | 1 | 0.25 | |
| MRSA ATCC43300 | 0.25 | 0.25 | |
| VMSA ATCC700788 | 4 | 32 | |
| VMSA ATCC700699 | 4 | 64 | |
| Enterococcus faecalis 19-1 | 4 | 1 | |
| LREfa 20-1 | 4 | 32 | |
| VREfa ATCC51575 | 4 | 0.5 | |
| G− | Acinetobacter baumannii 20-1 | 64 | 8 |
| Acinetobacter baumannii 20-2 | 64 | 0.06 | |
| Klebsiella pneumoniae ATCC700603 | >64 | 0.5 | |
| Klebsiella pneumoniae 15-1 | >64 | 0.25 | |
MRSA Methicillin-resistant Staphylococcus aureus, LRSA Linezolid-resistant Staphylococcus aureus, VMSA Vancomycin-intermediate Staphylococcus aureus, LREfa Linezolid-resistant Enterococcus faecalis, VREfa Vancomycin-resistant Enterococcus faecalis.